. Author manuscript; available in PMC: 2015 Dec 1.

Published in final edited form as: Mol Cancer Ther. 2014 Sep 24;13(12):3175–3184. doi: 10.1158/1535-7163.MCT-14-0358

Table 4. Summary of multivariate analysis for response, progression-free survival, and, overall survival.

Variable	Estimated Effect	95% CI	p-value
Response (SD ≥6 months/PR/CR)	OR^a
Metastatic sites ≤2 (vs >2)	10.62	1.52-74.09	0.017
Chemotherapeutic and targeted agents (vs chemotherapeutic or targeted agent only)	27.02	1.43-511.4	0.028
Progression-free survival	HR^b
Metastatic sites ≤2 (vs >2)	0.44	0.26-0.75	0.003
Chemotherapeutic and targeted agents (vs chemotherapeutic or targeted agent only)	0.38	0.22-0.633	0.0002
PI3K pathway inhibitors, yes (vs no)	0.49	0.27-0.88	0.018
Anti-angiogenic agents, yes (vs no)	0.52	0.29-0.91	0.023
Overall survival	HR^b
MDACC score ≤2 (vs >2)	0.25	0.15-0.41	<0.0001

OR>1 is associated with higher response.

HR<1 is associated with longer progression-free survival or overall survival.

Abbreviations: CR, complete response; CI, confidence interval; HR, hazards ratio; OR, odds ratio; PR, partial response; SD, stable disease; MDACC, MD Anderson Cancer Center Figure Legend